Palmitoylethanolamide/Polydatin

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamePalmitoylethanolamide/Polydatin
Drug Alias NamePalmitoylethanolamide/TranspolydatinPolydatin/Palmitoylethanolamide
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionPlatelet aggregation inhibitorsPeroxisome proliferator-activated receptor α agonistsCannabinoid receptor agonists +[4] 
TargetsCannabinoid receptorPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsYes PalmitoylethanolamidePolydatin
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Cagliari
China Registration ClassN/A

Develop Information

Active CompaniesRDC Clinical Pty Ltd
Inactive CompaniesN/A
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A